Trachoma

Trachoma is a bacterial eye disease associated with repeated conjunctival infection by Chlamydia trachomatis ^[1][2]. In the provided sources, it is framed as the etiologic agent of trachoma and as a strict intracellular human pathogen ^[3]. The condition is also described in surveillance and public-health literature as a neglected tropical disease under elimination efforts ^[1].

The clinical course described in the sources begins in childhood with repeated episodes of conjunctival infection and recurrent conjunctivitis, referred to as active trachoma ^[1]. With ongoing or untreated disease, the conjunctiva may become scarred, a stage termed cicatricial trachoma ^[1]. Later complications can include in-turned eyelashes, described as trachomatous trichiasis or entropion, which may be blinding ^[1][2]. The sources characterize these as the key sight-threatening sequelae, but more granular symptom timing or grading details are not yet available from the provided material ^[1][2].

Trachoma is reported as the leading or most common infectious cause of blindness in the cited sources ^[1][2]. It mainly affects the poorest and most rural communities, particularly where access to water and hygiene facilities is limited ^[1]. Another source describes occurrence in resource-poor areas with inadequate hygiene, aligning the disease with social and environmental deprivation ^[2]. By December 2024, 21 countries had eliminated trachoma as a public-health problem, while some populations still had persistent or recrudescent active trachoma that could complicate elimination targets ^[1].

The provided sources indicate transmission in settings where children with unclean faces share infected ocular secretions ^[2]. Repeated conjunctival infection in childhood is the central exposure pattern described, but the snippets do not give a more detailed mechanism beyond ocular secretions and hygiene-related contact ^[1][2]. Source-backed detail on persistence outside the host or specific environmental transmission routes is not yet available ^[1][2].

The sources identify the poorest and most rural communities as the main affected populations, especially where water access and hygiene facilities are limited ^[1]. Children are central to transmission and early infection, while women are noted as more likely to experience blinding complications in some settings because they often serve as caregivers for infected children from a young age ^[1]. Beyond these groups, source-backed detail on additional risk categories is not yet available ^[1][2].

The sources describe the WHO-supported SAFE strategy as the main public-health control package: surgery for trachomatous trichiasis, antibiotic mass drug administration, facial cleanliness, and environmental improvement ^[1][2]. These measures are presented as elimination-oriented interventions that have already produced substantial success in several countries ^[1][2]. No vaccine is reported in the provided material ^[3].

1. 1Habtamu E et al. Trachoma. Lancet. 2025 May 24. PMID: 40412861. doi: 10.1016/S0140-6736(25)00551-3.PubMed: https://pubmed.ncbi.nlm.nih.gov/40412861/
2. 2Taylor HR et al. Trachoma. Lancet. 2014 Dec 13. PMID: 25043452. doi: 10.1016/S0140-6736(13)62182-0.PubMed: https://pubmed.ncbi.nlm.nih.gov/25043452/
3. 3Jury B et al. Molecular pathogenesis of Chlamydia trachomatis. Front Cell Infect Microbiol. 2023. PMID: 37920447. doi: 10.3389/fcimb.2023.1281823.PubMed: https://pubmed.ncbi.nlm.nih.gov/37920447/